Here, we also show in ex vivo studies that treatment of tissue with MK2i leads to decreased IL-1β, IL-6, and TNFα, which is in line with our previous work as they are known to be involved in chronic inflammation in IBD. This evidence concerns the gene IL1B and inflammatory bowel disease.